News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AstraZeneca PLC (AZN) Seeks Partner For Potential $5 Billion Alzheimer's Blockbuster


5/7/2014 8:08:34 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

AstraZeneca, fighting a $106 billion bid approach from Pfizer, is talking to other companies as it seeks a partnering deal for its experimental Alzheimer's drug. Briggs Morrison, global head of medicines development, said AstraZeneca was talking to companies with more experience of Alzheimer's about a deal to share development of its so-called BACE inhibitor drug, which is set to enter late-stage Phase III development. A deal to share Phase III costs and share eventual profits was probably the easiest approach, he told reporters on Wednesday, but AstraZeneca could also out-license the product and take a royalty on any eventual sales.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters


comments powered by Disqus
Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES